Cargando…

An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany

BACKGROUND: This study aimed to evaluate cost-utility of baroreflex activation therapy (BAT) using the Barostim neo™ device (CVRx Inc., Minneapolis, MN, USA) compared with optimized medical management in patients with advanced chronic heart failure (NYHA class III) who were not eligible for treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borisenko, Oleg, Müller-Ehmsen, Jochen, Lindenfeld, JoAnn, Rafflenbeul, Erik, Hamm, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085633/ https://www.ncbi.nlm.nih.gov/pubmed/30092774 http://dx.doi.org/10.1186/s12872-018-0898-x

Ejemplares similares

Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States
por: Bisognano, John, et al.
Publicado: (2021)

Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure
por: Lindenfeld, JoAnn, et al.
Publicado: (2021)

Endovascular Baroreflex Amplification With the MobiusHD Device in Patients With Heart Failure and Reduced Ejection Fraction: Interim Analysis of the First-in-Human Results
por: Piayda, Kerstin, et al.
Publicado: (2022)

Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists
por: Pipilas, Alexandra, et al.
Publicado: (2022)

Role of Diuretics and Ultrafiltration in Congestive Heart Failure
por: Shchekochikhin, Dmitry, et al.
Publicado: (2013)

Cost-utility analysis of bariatric surgery compared with conventional medical management in Germany: a decision analytic modeling
por: Borisenko, Oleg, et al.
Publicado: (2017)

Baroreflex activation therapy: a new approach to the management of advanced heart failure with reduced ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2017)

Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials
por: Coats, Andrew J.S., et al.
Publicado: (2022)

Respiratory patterns and baroreflex function in heart failure
por: Radaelli, Alberto, et al.
Publicado: (2023)

A case report of ivabradine used for heart rate control of atrial fibrillation in acute decompensated heart failure
por: Hardison, Edward, et al.
Publicado: (2022)

Considerations for Heart Failure Care During the COVID-19 Pandemic
por: DeFilippis, Ersilia M., et al.
Publicado: (2020)

In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction
por: Cox, Zachary L, et al.
Publicado: (2022)

Medication regimen complexity in ambulatory older adults with heart failure
por: Cobretti, Michael R, et al.
Publicado: (2017)

Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study
por: Gronda, Edoardo, et al.
Publicado: (2014)

Markers of diuretic resistance in emergency department patients with acute heart failure
por: Doering, Andrew, et al.
Publicado: (2017)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
por: Pellicori, Pierpaolo, et al.
Publicado: (2020)

Acute Effects of Vagotomy on Baroreflex Equilibrium Diagram in Rats with Chronic Heart Failure
por: Kawada, Toru, et al.
Publicado: (2016)

Baroreflex activation therapy in advanced heart failure therapy: insights from a real‐world scenario
por: Guckel, Denise, et al.
Publicado: (2022)

Comparison of clinical symptoms and bioimpedance to pulmonary capillary wedge pressure in heart failure
por: Polcz, Monica, et al.
Publicado: (2022)

Calibration of Baroreflex Equilibrium Diagram Based on Exogenous Pressor Agents in Chronic Heart Failure Rats
por: Kawada, Toru, et al.
Publicado: (2015)

The efficacy of baroreflex activation therapy for heart failure: A meta-analysis of randomized controlled trials
por: Cai, Guoqiang, et al.
Publicado: (2020)

Impaired Baroreflex Function in an Ovine Model of Chronic Heart Failure Induced by Multiple Coronary Microembolizations
por: Abukar, Yonis, et al.
Publicado: (2019)

Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review
por: Molina‐Linde, Juan Máximo, et al.
Publicado: (2023)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Group Dynamics and Allocation of Advanced Heart Failure Therapies—Heart Transplants and Ventricular Assist Devices—By Gender, Racial, and Ethnic Group
por: Breathett, Khadijah, et al.
Publicado: (2023)

Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator
por: Hadwiger, Moritz, et al.
Publicado: (2020)

Baroreflex mechanisms and response to exercise in patients with heart disease
por: Fukuma, Nagaharu, et al.
Publicado: (2012)

Clinical and haemodynamic correlates of heart rate turbulence as a non-invasive index of baroreflex sensitivity in chronic heart failure
por: La Rovere, Maria Teresa, et al.
Publicado: (2011)

Contemporary Management of Secondary Mitral Regurgitation
por: Goel, Kashish, et al.
Publicado: (2020)

Editorial: Baroreflex activation is a novel therapy for heart failure independent of left ventricular systolic function
por: Kishi, Takuya
Publicado: (2014)

Updates on Baroreflex Activation Therapy and Vagus Nerve Stimulation for Treatment of Heart Failure With Reduced Ejection Fraction
por: Babar, Natasha, et al.
Publicado: (2022)

Ventricular-Vascular Uncoupling in Heart Failure: Effects of Arterial Baroreflex-Induced Sympathoexcitation at Rest and During Exercise
por: Mannozzi, Joseph, et al.
Publicado: (2022)

Cardiopulmonary function during exercise in heart failure with reduced ejection fraction following baroreflex activation therapy
por: Nottebohm, Pia I., et al.
Publicado: (2022)

Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single‐centre experience
por: Blanco, Carola, et al.
Publicado: (2023)

Impact of medication adherence on the efficacy of Baroreflex activation therapy
por: Schäfer, Ann‐Kathrin C., et al.
Publicado: (2022)

Safety and efficacy of baroreflex activation therapy for heart failure with reduced ejection fraction: a rapid systematic review
por: Schmidt, Rodrigo, et al.
Publicado: (2020)

Oscillatory Pattern of Sympathetic Nerve Bursts Is Associated With Baroreflex Function in Heart Failure Patients With Reduced Ejection Fraction
por: Toschi-Dias, Edgar, et al.
Publicado: (2021)

Baroreflex sensitivity but not microvolt T-wave alternans can predict major adverse cardiac events in ischemic heart failure
por: Kaufmann, Damian K., et al.
Publicado: (2022)

Extracorporeal Membrane Oxygenation as a Treatment for Branch Pulmonary Artery Rupture Following Right Heart Catheterisation
por: Agrawal, Vineet, et al.
Publicado: (2022)

Early urine electrolyte patterns in patients with acute heart failure
por: Collins, Sean P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vnpedsbba7vm2f3nc5913vphdv